Branding & Marketing

MMIT Reality Check on CLL (Nov 2018)

November 2, 2018

According to our recent payer coverage analysis for chronic lymphocyctic leukemia (CLL) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

According to our recent payer coverage analysis for chronic lymphocyctic leukemia (CLL) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for CLL treatments shows that more than half of the covered lives under Medicare formularies are restricted.

Trends: The FDA approved Verastem, Inc.’s Copiktra (duvelisib) for the treatment of adults with relapsed or refractory CLL after at least two treatments.

 

MMIT Reality Check on Hypertension (Oct 2018)

October 26, 2018

According to our recent payer coverage analysis for hypertension treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for hypertension treatments shows that about 44% of the lives under commercial formularies are unrestricted.

According to our recent payer coverage analysis for hypertension treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for hypertension treatments shows that about 44% of the lives under commercial formularies are unrestricted.

Trends: With a wide variety of generic drugs available, brand name hypertension drugs are rarely prescribed to patients, and costs remain low. Via AIS Health.

MMIT Reality Check on Respiratory (Asthma/COPD) (Oct 2018)

October 19, 2018

According to our recent payer coverage analysis for asthma and COPD treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: About 4% of the lives are restricted under commercial and health exchange policies,

According to our recent payer coverage analysis for asthma and COPD treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: About 4% of the lives are restricted under commercial and health exchange policies, while about 9% of Medicare beneficiaries are covered.

Trends:  The new drugs give payers some cost-saving options and might pull some market share from Advair due to the price difference.

MMIT Reality Check on Hepatitis C (Oct 2018)

October 12, 2018

According to our recent payer coverage analysis for Hepatitis C treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: For more than 54% of the covered lives,

According to our recent payer coverage analysis for Hepatitis C treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: For more than 54% of the covered lives, payer pharmacy benefit formularies do not require step therapy (ST).

Trends:  Express Scripts Holding Co. is adding 48 new exclusions on its 2019 National Preferred Formulary, including AbbVie Inc.’s hepatitis C medication Mavyret.

Trends That Matter for Specialty Drug Management

October 11, 2018

Specialty drugs continue to be a concern for large employers, according to The Large Employers’ 2019 Health Care Strategy and Plan Design Survey by the National Business Group on Health (NBGH), AIS Health reported.

NBGH surveyed its corporate members in May and June on what they are doing for 2019. When NBGH asked employers about specialty pharmacy benefit management techniques, respondents selected more aggressive utilization management protocols as the top strategy,

Specialty drugs continue to be a concern for large employers, according to The Large Employers’ 2019 Health Care Strategy and Plan Design Survey by the National Business Group on Health (NBGH), AIS Health reported.

NBGH surveyed its corporate members in May and June on what they are doing for 2019. When NBGH asked employers about specialty pharmacy benefit management techniques, respondents selected more aggressive utilization management protocols as the top strategy, with 64% citing this, followed by having employees get specialty drugs through a specialty pharmacy or the specialty department of the health plan or PBM, cited by 58%. At 44%, site-of-care management notched the third top technique.

MMIT Reality Check on Hereditary Angioedema (Sep 2018)

October 5, 2018

According to our recent payer coverage analysis for Hereditary Angioedema treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: Half of Lives under commercial formulary are restricted.

According to our recent payer coverage analysis for Hereditary Angioedema treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: Half of Lives under commercial formulary are restricted.

Trends: Express Scripts Holding Co. is adding 48 new exclusions on its 2019 National Preferred Formulary.